Comparison of incidences of graft-versus-host disease in subgroups of patients treated by bulk dose regimen
. | <1.5 × 108 (n = 11) . | ≥1.5 × 108 (n = 11) . |
---|---|---|
Relapse stage | ||
Cytogenetic | 2 | 5 |
Hematologic–CP | 8 | 5 |
Hematologic–AP | 1 | 1 |
Complete remission | 6 (54%) | 9 (81%) |
GVHD: | ||
Acute | ||
Grades 0-1 | 6 | 6 |
Grade 2 | 1 | 3 |
Grades 3-4 | 4 | 2 |
Chronic | ||
None/limited | 6 | 5 |
Extensive | 4 | 6 |
. | <1.5 × 108 (n = 11) . | ≥1.5 × 108 (n = 11) . |
---|---|---|
Relapse stage | ||
Cytogenetic | 2 | 5 |
Hematologic–CP | 8 | 5 |
Hematologic–AP | 1 | 1 |
Complete remission | 6 (54%) | 9 (81%) |
GVHD: | ||
Acute | ||
Grades 0-1 | 6 | 6 |
Grade 2 | 1 | 3 |
Grades 3-4 | 4 | 2 |
Chronic | ||
None/limited | 6 | 5 |
Extensive | 4 | 6 |
GVHD, graft-versus-host disease.
Lymphocyte doses ranged from <1.5 × 108/kg to >1.5 × 108/kg.